AURANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Aura Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$6.29+0.19 (+3.11%)
Close on Oct 19, 2026
- Market cap
- $596.69M
- P/E (TTM)
- –
- Dividend yield
- –
Aura Biosciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Aura Biosciences | Industry median |
|---|---|---|
| Market Cap | $652.30M | $197.05M |
| Enterprise Value | $584.47M | $106.56M |
| PB Ratio | 2.07 | 2.14 |
| P/TBV Ratio | 2.07 | 2.46 |
Income (trailing twelve months)
| Measure | Aura Biosciences | Industry median |
|---|---|---|
| Operating Income | -$138.08M | -$21.44M |
| Pretax Income | -$130.93M | -$14.45M |
| Net Income | -$131.01M | -$22.46M |
| EBITDA | -$138.08M | -$16.91M |
| EPS (Diluted) | -$1.76 | -$0.83 |
Returns
| Measure | Aura Biosciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | -53.5% | -53.1% |
| Return on Assets (ROA) | -47.4% | -41.0% |
| Return on Invested Capital (ROIC) | -69.3% | -32.0% |
| Return on Capital Employed (ROCE) | -42.0% | -37.8% |
Balance sheet
| Measure | Aura Biosciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $67.84M | $62.42M |
| Net Cash (Debt) | $67.84M | $15.68M |
| Net Cash Per Share | $0.65 | $0.65 |
| Equity (Book Value) | $315.27M | $48.79M |
| Book Value Per Share | $3.04 | $1.36 |
| Tangible Book Value | $315.27M | $23.06M |
| Working Capital | $309.47M | $75.77M |
Financial position
| Measure | Aura Biosciences | Industry median |
|---|---|---|
| Current Ratio | 16.82 | 3.30 |
| Quick Ratio | 3.47 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Aura Biosciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$103.01M | -$12.35M |
| Capital Expenditures | -$344.00K | -$1.06M |
| Free Cash Flow | -$103.35M | -$20.28M |
| FCF Per Share | -$1.00 | -$0.41 |
Efficiency
| Measure | Aura Biosciences | Industry median |
|---|---|---|
| Profits Per Employee | -$1.16M | -$732.08K |
| Employee Count | 113 | 73 |
Dividends and yields
| Measure | Aura Biosciences | Industry median |
|---|---|---|
| Earnings Yield | -20.1% | -21.2% |
| FCF Yield | -15.8% | -7.64% |
Shares
| Measure | Aura Biosciences | Industry median |
|---|---|---|
| Shares Outstanding | 103,705,000 | 59,128,900 |
| Shares Change (YoY) | 42.2% | 11.1% |
| Shares Change (QoQ) | 61.3% | 0.54% |
| Float | 95,893,400 | 48,744,500 |
| Shares Held by Insiders | 7.53% | 11.8% |
| Shares Held by Institutions | 94.8% | 59.4% |
Taxes
| Measure | Aura Biosciences | Industry median |
|---|---|---|
| Income Tax | $81.00K | $91.50K |
Scores
| Measure | Aura Biosciences | Industry median |
|---|---|---|
| Altman Z-Score | 9.42 | 0.10 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Aura Biosciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.